Mercy BioAnalytics secured $59 million in Series B funding to support the commercialization of its blood-based ovarian cancer screening tests set for initial rollout in 2026. The company's Halo testing platform detects tumor-associated protein combinations on extracellular vesicles in the blood, enabling high specificity. In addition to population screening and diagnostic aid for pelvic masses, Mercy plans to develop a complementary lung cancer screening test. The financing will facilitate regulatory milestones and expanded early-access programs, with backing from prominent investors including Novalis and Sozo Ventures.